



Astec LifeSciences Ltd.

Dated: 5th February, 2011

To,
The Department of Corporate Services
National Stock Exchange Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra, Mumbai-400051

Ref: "ASTEC"

Sub: Outcome of Board Meeting.

Dear Sir,

This is to inform you that the Board of Directors at their meeting held on 5th February, 2011 has:

- 1) Approved the Consolidated Unaudited Financial Results for the quarter & Nine Month ended 30.12.2010.
- 2) Approved the Limited Review Report on Unaudited Financial Results for the quarter ended 31.12.2010.

Please take the same on your records.

Thanking you,

Yours Sincerely,

For Astec LifeSciences Limited

Vikas R. Chomal
Company Secretary & Compliance Officer



Encl: as above

ASTEC LIFESCIENCES LTD

Regd. Office : 5/5A, Kamanwala Chambers, Sir P.M. Road, Fort, Mumbai: 400001.

Unaudited Financial Results for the Quarter/Nine Months ended 31st December' 2010

Standalone										Consolidated									
Sr. No	Particulars	Quarter				Nine Months				Year ended 31/03/2010	Quarter				Nine Months				Year ended 31/03/2010
		Ended 31/12/2010	Ended 31/12/2009	Ended 31/12/2010	Ended 31/12/2009	Ended 31/03/2010	Ended 31/12/2010	Ended 31/12/2009	Ended 31/12/2010		Ended 31/12/2009	Ended 31/12/2010	Ended 31/12/2009						
		(Unaudited)				(Audited)	(Unaudited)				(Audited)								
1	a) Sales / Income from operations b) Other Operating Income Less: Excise duty Net sales / Income from operations	2,680.32 36.13 60.78 2,655.67	3,066.34 12.04 114.95 2,963.43	9,016.30 126.22 257.45 8,885.07	8,343.20 37.36 379.04 8,001.52	11,638.50 102.36 455.02 11,285.84	2,683.02 36.13 60.78 2,658.37	3,069.04 12.04 114.95 2,966.13	9,024.40 126.22 257.45 8,893.17	8,351.30 37.36 379.04 8,009.62	11,649.30 105.93 455.02 11,300.21								
2	Total expenditure a) (Increase) / Decrease in stock/ WIP b) Cost of materials and utilities c) Purchases of Traded Goods d) Employees cost e) Depreciation f) Other expenditure g) Total expenditure	165.93 1,354.69 470.71 114.65 129.28 132.46 2,367.72	(333.41) 2,153.41 240.45 77.37 97.43 105.21 2,340.46	(922.73) 5,553.34 1,585.78 290.24 382.68 343.59 7,703.61	(192.75) 4,915.95 751.78 235.67 287.62 274.16 6,272.43	(44.11) 6,790.95 1,210.60 322.28 410.08 367.70 9,057.50	165.93 1,354.69 470.71 114.65 130.30 133.96 2,370.24	(322.25) 2,368.30 240.45 77.37 99.22 119.61 2,342.25	(922.73) 7,139.12 1,585.78 290.24 386.54 347.29 7,711.17	(181.59) 4,890.39 751.78 235.67 292.99 288.56 6,277.80	(44.11) 6,790.95 1,210.60 322.28 416.39 372.75 9,068.86								
3	Profit from operations before other income and interest	287.95	622.97	1,181.46	1,729.09	2,228.34	288.13	623.88	1,182.00	1,731.82	2,231.35								
4	Profit Before Interest and exceptional Items	287.95	622.97	1,181.46	1,729.09	2,228.34	288.13	623.88	1,182.00	1,731.82	2,231.35								
5	Interest and finance charges	92.93	118.46	298.68	456.83	511.48	92.93	119.27	298.68	458.87	513.47								
6	Profit after interest but before Exceptional Items	195.02	504.51	882.78	1,272.26	1,716.86	195.20	504.61	883.32	1,272.95	1,717.88								
8	Profit before tax	195.02	504.51	882.78	1,272.26	1,716.86	195.20	504.61	883.32	1,272.95	1,717.88								
9	Provision for Current Taxes	38.80	124.16	176.35	216.29	333.17	38.86	124.19	176.52	216.52	333.68								
10	Net Profit after tax	156.22	380.35	706.43	1,055.97	1,383.68	156.34	380.42	706.80	1,056.43	1,384.20								
11	Minority Interest in Net Profit of Subsidiary	-	-	-	-	-	0.04	0.03	0.16	0.28	0.18								
12	Net Profit After Tax	156.22	380.35	706.43	1,055.97	1,383.68	156.30	380.39	706.64	1,056.15	1,384.02								
13	Exceptional Items (Prior Period Tax Liability)	0.16	-	7.51	-	62.78	0.16	-	7.51	-	62.78								
14	Net Profit After Tax & Exceptional Item	156.06	380.35	698.92	1,055.97	1,320.90	156.14	380.39	699.13	1,056.15	1,321.24								
15	Paid-up equity share capital (Face Value Rs. 10/-)	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91	1,692.91								
16	Earnings per share (EPS)																		
	Before Extraordinary items																		
	- Basic & Diluted	0.92	2.25	4.17	6.24	8.17	0.92	2.25	4.17	6.24	8.18								
	- Weighted Average	0.92	2.70	4.17	9.61	11.38	0.92	2.70	4.17	9.62	11.38								
	- Annualised (Weighted Average)	3.69	10.81	5.56	12.82	11.38	3.69	10.81	16.70	12.82	11.38								
	After Extraordinary items																		
	- Basic & Diluted	0.92	2.25	4.13	6.24	7.80	0.92	2.25	4.13	6.24	7.80								
	- Weighted Average	0.92	2.70	4.13	9.61	10.86	0.92	2.70	4.13	9.62	10.86								
	- Annualised (Weighted Average)	3.69	10.81	5.50	12.82	10.86	3.69	10.81	5.51	12.82	10.86								
17	Public shareholding	7,500,150	7,500,150	7,500,150	7,500,150	7,500,150	7,500,150	7,500,150	7,500,150	7,500,150	7,500,150								
	- No of shares	44.30%	44.30%	44.30%	44.30%	44.30%	44.30%	44.30%	44.30%	44.30%	44.30%								
	- Percentage of shareholding																		



18 Promoters and promoter group shareholding

a) Pledged / Encumbered									
- No of shares	-	-	-	-	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoters and promoter group share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non-encumbered									
- No of shares	9,428,980	9,428,980	9,428,980	9,428,980	9,428,980	9,428,980	9,428,980	9,428,980	9,428,980
- Percentage of shares (as a % of the total shareholding of promoters and promoter group share capital of the company)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	55.70%	55.70%	55.70%	55.70%	55.70%	55.70%	55.70%	55.70%	55.70%

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on February 05, 2011
- 2 The company has only one reportable segment i.e. Agrochemicals & Pharma Intermediates.
- 3 Above Financial Results includes Financials results of M/s Behram Chemicals Pvt. Ltd. which is a 65.63% subsidiary of Astec LifeSciences Ltd.
- 4 The above Financial Results does not include results of M/s Astec Crop Care Pvt. Ltd. 100% subsidiary of Astec LifeSciences Ltd. Because operation has not started yet into subsidiary company.
- 5 Provision for deferred tax liability shall be made at the end of the year.
- 6 The Company has out of the total public issue proceeds of Rs. 6150 Lacs made in the previous financial year, so far utilised Rs. 5225.50 Lacs towards objects of the issue. Pending utilisation of the balance proceeds, the same have been temporarily invested in Debt Mutual Funds, Bank Fixed Deposits.
- 7 Investor complaints for the quarter ended 31.12.2010 : Received: 4 Disposed Off : 4 Lying Unresolved: Nil
- 8 The Figures for the corresponding period of previous year have been restated, regrouped wherever necessary to make them comparable.

For Astec LifeSciences Limited

sd/-

(Ashok V Hiremath)

Chairman & Managing Director

Mumbai, February 05, 2011





P.M. Kathariya & Co.

Chartered Accountants

Room No. 6, Kermani Bldg., 4th Floor, 27
Sir P. M. Road, Fort, Mumbai - 400 001.

Tel. : 66315862, Telefax: 22856615, R: 28728803

Mobile : 9821034665

Email: pmkathariya@rediffmail.com

pmkathariya@gmail.com

Annexure V to Clause 41

Review Report to **ASTEC LIFESCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of Astec LifeSciences Limited for the period ended 31st December, 2010 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai

Date: 04/02/2011



For P. M. KATHARIYA & CO.
Chartered Accountants

[Signature]

C.A. - P. M. KATHARIYA
(Proprietor)
M. No. 31315